Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma 1Endometrial Neoplasms 1

Interventions

pembrolizumab 18Nivolumab 6Radiotherapy 5Paclitaxel 5Trastuzumab 4Specimen Handling 4Ipilimumab 4tisotumab vedotin 3temsirolimus 3olaparib 3lenvatinib 3X-Rays 3Taxes 3Surveys and Questionnaires 3Early Intervention, Educational 3Cyclophosphamide 3Carboplatin 3Biopsy 3spartalizumab 2sargramostim 2rucaparib 2palbociclib 2fludarabine 2epacadostat 2enzalutamide 2durvalumab 2cabozantinib 2atezolizumab 2aflibercept 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × TAS-116 × Genitourinary × Clear all
NCT05655598 2024-09-19

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Brown University

Phase 1 Withdrawn
GenitourinaryGynecologicSarcoma

Urinary Bladder Neoplasms, Sarcoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡